Investigation of Urinary Biomarkers for the Diagnosis of Insulin Resistance
NCT ID: NCT04010903
Last Updated: 2024-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
304 participants
INTERVENTIONAL
2019-09-16
2024-07-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Blood and urine levels of BCAAs will be correlated with HOMA index to assess and quantify insulin resistance.
Identification and quantification of urine BCAAs by an innovative method based on synthetic biology will also be performed.
Correlations between mass spectometry and the innovative detection method of BCAAs will be searched.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
UroCAD for Hematuria Evaluation--A Prospective, Multi-center Study
NCT05893316
Measurement of MRP2 Function Using Urinary Coproporphyrins
NCT00746044
Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma
NCT01572857
Quantitative Renal Uptake Using TC99m DMSA in Hypertensive &/or Diabetic Patients.
NCT03123237
Urine pH as a Predictor of Diabetes
NCT01017848
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Persons included will be:
110 persons with BMI\>27 and HOMA \>4 with no diabetes 110 persons with BMI\>27 and HOMA \< 4 with no diabetes 110 persons with BMI \< 27 and HOMA \<4 with no diabetes, including at least 50 men and 50 women, 30 aged 18-35, 30 aged 36-55, 30 aged 56-75.
Urine BCAAs will be measured by both mass spectrometry and the innovative method based on synthetic biology.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HEALTHY SUBJECTS
SUBJECTS WITH BMI\<27 and HOMA\<4
assessment of biomarkers of insulin resistance
blood and urine sample collection for assays of BCAAs
OVERWEIGHT NON INSULINRESISTANT PATIENTS
SUBJECTS WITH BMI\>27 and HOMA\<4
assessment of biomarkers of insulin resistance
blood and urine sample collection for assays of BCAAs
OVERWEIGHT INSULINRESISTANT PATIENTS
SUBJECTS WITH BMI\>27 and HOMA\>4
assessment of biomarkers of insulin resistance
blood and urine sample collection for assays of BCAAs
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
assessment of biomarkers of insulin resistance
blood and urine sample collection for assays of BCAAs
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* according to studied subpopulations: BMI\<27 and HOMA \<4, BMI\>27 and HOMA\>4, BMI\>27 and HOMA\<4
Exclusion Criteria
* active or suspected chronic infection
* treatment affecting insulin sensitivity
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre National de la Recherche Scientifique, France
OTHER
Sys2Diag, Mixt laboratory CNRS/Alcediag, Montpellier
UNKNOWN
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
EMILIE BARDE
Role: STUDY_DIRECTOR
UH Montpellier
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UH Montpellier
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19_0077
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.